session 4 - PE screening in T1.pptx
À propos
Ce fichier PPTX, contenant 8 diapositives, a été envoyé sur fichier-pps.fr le 16 octobre 2023 à 21:53,
à partir de l'adresse IPv4 82.64.*.*.
La présente page de téléchargement a été vue 270 fois depuis l'envoi du fichier.
Taille du fichier: 1640 Ko
Identifiant unique: #61874
Fichier public
Aperçu du fichier
Aperçu texte:
Session 4: PE screening in T1 Answer What are the parameters included in the risk calculation for PE screening? Why is it needed to calculate MoMs? Trends in MoM healthy / PE for the main parameters What is the GA window for the screening? What is the difference between detection rate and sensitivity? What is the difference between false positive rate and specificity? 1 Proprietary & Confidential Session 4: PE screening in T1 2 Tan, 2018 Boutin, 2020 Cuenca, 2023 Riishede, 2023 Genoux, 2018 Chaemsaithong, 2019 Country Europe Canada Spain Denmark France Asia Assigne ment Daniel Caroline Idoia Ada Sophie Proprietary & Confidential Session 4: PE screening in T1 Tan, 2018 Boutin, 2020 Nb controls Nb PE < W34 Nb PE < W37 Nb PE > W37 Key characteristics of the population Ethnicity BMI Age > 35 Chronic HTN Diabetes SLE 3 Proprietary & Confidential Cuenca, 2023 Riishede, 2023 Genoux, 2018 Chaemsaithong, 2019 Session 4: PE screening in T1 Tan, 2018 MoMs MAP Controls/PE MoMs UtPI Controls/PE MoMs PlGF Controls/PE MoMs PAPPA Controls/PE 4 Proprietary & Confidential Boutin, 2020 Cuenca, 2023 Riishede, 2023 Genoux, 2018 Chaemsaith ong, 2019 Session 4: PE screening in T1 DR (10% FPR) PE before W34 Mat.factors+ MAP UtPI PlGF PAPP-A MAP+PlGF MAP+UtPI MAP+UtPI+PlGF MAP+UtPI+PAPP A MAP+UtPI+PlGF + PAPPA 5 Proprietary & Confidential Tan, 2018 Boutin, 2020 Cuenca, 2023 Riishede, 2023 Genoux, 2018 Chaemsaitho ng, 2019 Session 4: PE screening in T1 FMF DR SPR FPR Comments 6 Proprietary & Confidential NICE ACOG Session 4: PE screening in T1 Objections Aspirin is cheap, I give it to all pregnant women I already measure PAPPA, performance is equivalent to PlGF Why shall I screen for preeclampsia? There is not enough evidence! I do not need to screen for preeclampsia, I know which patient will get it I use NICE/ACOG and it’s working 7 Proprietary & Confidential Answer Session 3/4 • Effectiveness check 8 Proprietary & Confidential
Vos commentaires sur session 4 - PE screening in T1.pptx
Télécharger session 4 - PE screening in T1.pptx
Télécharger le fichier (.pptx, 1640 Ko)Partager ce PPS sur le Web et les réseaux sociaux
Lien permanent vers la page de téléchargement du fichier:
Code HTML - Recopiez ce code pour partager votre fichier PPTX sur un site Web ou un Blog